Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. März 2024 06:44 ET | Quelle: Landsbankinn hf.

Landsbankinn hf.: Acquisition by Landsbankinn of own shares under a buyback programme - end of acquisition period

On the 15th of February 2024, Landsbankinn announced that the Bank would offer to purchase shares from shareholders under the terms of a buyback programme during the period 19th of February 2024 to...
05. März 2024 06:44 ET | Quelle: Landsbankinn hf.

Landsbankinn hf.: Tilkynning um kaup Landsbankans á eigin hlutum – lok endurkaupatímabils

Þann 15. febrúar 2024 birti Landsbankinn tilkynningu um að bankinn byðist til að kaupa hluti af hluthöfum samkvæmt endurkaupaáætlun á tímabilinu 19.febrúar 2024 til og með 4. mars 2024. Á...
05. März 2024 05:18 ET | Quelle: Festi hf.

Festi hf.: Árs- og sjálfbærniskýrsla 2023

Árs- og sjálfbærniskýrsla Festi hf. fyrir árið 2023 hefur verið birt í tengslum við aðalfund félagsins sem verður haldinn miðvikudaginn 6. mars 2024 klukkan 10.00 í höfuðstöðvum félagsins að Dalvegi...
05. März 2024 05:18 ET | Quelle: Festi hf.

Festi hf.: Annual and Sustainability Report 2023

Festi hf. 2023 Annual and Sustainability Report has been published in connection with the Company's Annual General Meeting, which will be held on Wednesday, March 6, 2024, at the Company's...
05. März 2024 04:53 ET | Quelle: Novo Nordisk A/S

Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial

Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to...
05. März 2024 04:50 ET | Quelle: Totalkredit A/S

Korrektion: Ekstraordinære indfrielser (CK93) - Totalkredit A/S

Til Nasdaq Copenhagen Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Totalkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 1. marts...
05. März 2024 04:50 ET | Quelle: Totalkredit A/S

Correction: Prepayments (CK93) - Totalkredit A/S

To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 1 March 2024 in the attached file. ...
05. März 2024 04:11 ET | Quelle: Pharma Equity Group A/S

Pharma Equity Groups datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse fra Det Europæiske Patentkontor (EPO) om beslutningen om at tildele deres patent for lægemiddelsammensætninger til fremme af sårheling (RNX-022).

Pharma Equity Groups datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse fra Det Europæiske Patentkontor (EPO) om beslutningen om at tildele deres patent for lægemiddelsammensætninger...
05. März 2024 04:11 ET | Quelle: Pharma Equity Group A/S

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for...
05. März 2024 04:00 ET | Quelle: KommuneKredit

Ekstraordinære indfrielser (CK93)

KommuneKredit offentliggør hermed oplysninger om ekstraordinære indfrielser (CK93) pr. 1. marts 2024. Der er pr. opgørelsesdagen ingen ekstraordinære indfrielser. For yderligere...

Vorherige Seite

Nächste Seite